Author: Bella Hayes

Investing.com — Shares of Johnson & Johnson (NYSE:) fell 3% amid concerns regarding its cardiac ablation device, Varipulse. The movement comes after Wells Fargo (NYSE:) released a research report suggesting disruptions in the supply of Varipulse due to potential side effects that may have led to a temporary halt of its use in some regions of the United States. The report, spearheaded by analyst Larry Biegelsen, pointed to conversations with physicians and industry contacts indicating that Johnson & Johnson has possibly paused Varipulse procedures because of adverse events, including strokes. Biegelsen stated, “it’s unclear if a full pause has gone…

LONDON – Braveheart Investment Group plc (AIM: LON:) has announced the appointment of MAH, Chartered Accountants as its new auditor, replacing PKF Littlejohn LLP. The change was made public on Wednesday, with MAH set to oversee the audit for the fiscal year ending March 31, 2025. The decision to appoint MAH will be presented for shareholder approval at Braveheart’s 2025 Annual General Meeting. The transition comes after PKF Littlejohn LLP resigned from its auditing role for the investment company. PKF has stated that there are no significant matters related to its resignation that should be brought to the attention of…

Esquire Financial Holdings Inc (NASDAQ:). has reached an unprecedented milestone as its stock price soared to an all-time high of $81.89. The financial services company, with a market capitalization of $638 million, maintains strong financial health according to InvestingPro metrics, backed by a solid P/E ratio of 15.2 and encouraging revenue growth of 10.3% over the past year. This remarkable peak reflects a significant surge in investor confidence, marking a 72.47% increase over the past year. The company’s robust financial performance and strategic initiatives have fueled this impressive growth, rewarding shareholders with substantial gains and setting a new benchmark for…

Investing.com — Natural gas futures rose on Wednesday due to strong weather-driven demand across the United States. This increased demand coincides with a limited supply caused by some production freeze-offs. Despite a drop in prices in the prior session, colder forecasts for the third week of January are causing a revival of the upside, according to a note from Eli Rubin of EBW Analytics. Rubin pointed out that the market might be underestimating the scale of a significant national January storage draw. He added that the duration of freeze-offs might extend longer than initially thought. A below-average storage withdrawal for…

In a turbulent market environment, Wearable Devices Ltd. (WLDS) stock has plummeted to a 52-week low, trading at $1.32. According to InvestingPro data, the company’s financial health score stands at a concerning 1.5, labeled as “WEAK,” with a market capitalization of just $2.48 million. This significant downturn reflects a broader trend for the company, which has seen its stock value erode by an alarming 84.44% over the past year. While the company maintains more cash than debt on its balance sheet, InvestingPro analysis reveals it’s quickly burning through cash reserves, with a concerning negative EBITDA of $8.25 million. Investors have…

LONDON – ASA International Group plc (LSE: ASAI), a prominent global microfinance institution, has disclosed updated remuneration details for its directors. The announcement, made on January 08, 2025, outlines the compensation arrangements for the company’s top executives as per the Directors’ Remuneration Policy, which shareholders approved at the Annual General Meeting on June 15, 2023. Rob Keijsers, serving as the Interim Chief Executive Officer, receives a base salary of 234,640.50 annually, with an additional EUR 92,043 allowance for his interim role. His remuneration package also includes participation in the Long-Term Incentive Plan (LTIP) and a pension allowance of 10% of…

LONDON – ChallengerX plc (AQUIS: CXS) has announced the issuance of a Convertible Loan Note (CLN) to raise £120,000. The funds from this financial instrument are earmarked for due diligence on potential acquisitions and efforts to reinstate the trading of the company’s ordinary shares on the Aquis Stock Exchange. The CLN will carry an annual interest rate of 5%, with the first interest payment scheduled for June 30, 2025, and subsequent payments every six months. Under the terms of the loan, the amount raised will automatically convert into 120 million ordinary shares of the company at 0.1 pence each if…

VANCOUVER, BRITISH COLUMBIA – BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0), known for its proprietary Botanical Synthesis technology, has reported a year of significant transformation and growth, according to a shareholder letter from CEO Ilan Sobel. InvestingPro data reveals impressive revenue growth of 111.68% over the last twelve months, with analysts projecting continued sales growth this year. The company launched its CDMO Services division, partnered with Tate & Lyle, and doubled its core VINIA® capsule business in 2024. Additionally, BioHarvest successfully introduced VINIA Inside products, targeting a broader consumer market. The CDMO Services division, unveiled in early March…

Handling over 1 million 911 calls annually, San Francisco’s DEM will leverage NICE’s automatedsolutions to bolster services to citizens, first responders and partner agencies HOBOKEN, N.J.–(BUSINESS WIRE)–NICE (: NICE) today announced that the San Francisco Department of Emergency Management (DEM) has chosen NICE Inform Elite, one of the solutions in NICE’s Evidencentral platform, to bolster services to residents, first responders and partner agencies. The City’s dispatch center is one of the top 25 busiest in the U.S., handling over one million emergency calls annually. San Francisco DEM, a NICE customer since 2006, will be upgrading to NICE’s advanced capabilities. NICE…

HACKENSACK, NJ – Champions Oncology , Inc. (NASDAQ:), a research organization specializing in oncology with a focus on technology-enabled testing services, has announced the expansion of its bioanalytical services with new technology and leadership. The company has integrated several Cytek Aurora flow cytometers into its portfolio and appointed Troy Tremaine, MBA, as the new head of Bioanalytical Commercial Strategy. The integration of Cytek Aurora technology is set to enhance the company’s existing spectral and conventional flow cytometry capabilities, allowing for more complex spectral analysis. This strategic move is expected to better serve Champions Oncology’s clients by offering more in-depth analytical…